---
title: "Bristol releases positive mid-stage results of Breyanzi in marginal zone lymphoma"
date: "2025-02-10 17:21:05"
summary: "Bristol Myers Squibb (NYSE:BMY) said that a phase 2 study of Breyanzi (lisocabtagene maraleucel)) in marginal zone lymphoma met its primary endpoint. The oncologic showed a statistically significant and clinically meaningful overall response rate. The study, TRANSCEND FL, also met the secondary endpoint of complete response rate. The trial has..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1617236488/image_1617236488.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Bristol Myers Squibb (NYSE:[BMY](https://seekingalpha.com/symbol/BMY "Bristol-Myers Squibb Company")) said that a phase 2 study of Breyanzi (lisocabtagene maraleucel)) in marginal zone lymphoma met its primary endpoint.
* The oncologic showed a statistically significant and clinically meaningful overall response rate.
* The [study](https://seekingalpha.com/pr/19996311-bristol-myers-squibb-announces-positive-topline-results-for-breyanzi-lisocabtagene-maraleucel "study"), TRANSCEND FL, also met the secondary endpoint of complete response rate. The trial has enrolled patients with indolent B-cell non-Hodgkin lymphoma and the latest results were in a MZL cohort.

[seekalpha](https://seekingalpha.com/news/4405558-bristol-releases-positive-mid-stage-results-breyanzi-marginal-zone-lymphoma)
